Interstitial lung disease accompanied by anti-melanoma differentiation-associated gene 5 positive dermatomyositis is often rapidly progressive and associated with poor prognosis. In this study, a combined immunosuppressive regimen of high-dose glucocorticoids, tacrolimus and intravenous cyclophosphamide proved more effective than treatment with high-dose glucocorticoids and stepwise addition of an immunosuppressant in a historical control group.
Pearls & Myths: Experts Offer Advice & Dispel Myths
GCA, GPA, myositis, new research—rheumatology care keeps clinicians on their toes & requires them to stay up to date…
RheumPAC Announces New Donor Benefits in 2020
Donors at each giving level will receive recognition and special benefits at the ACR’s 2020 annual meeting.
15% E/M Services Reimbursement Hike a Win for Rheumatology
ACR advocacy leaders are celebrating a 15% planned increase in reimbursement for rheumatology evaluation and management services and are calling on members to thank Congress.
Changes & Additions to RISE Measures in 2020
Using RISE? Check out the updates for 2020, including five new measures available only through the RISE registry.
The Rheumatology Research Foundation Welcomes New Leaders
The Rheumatology Research Foundation has appointed S. Louis Bridges Jr., MD, PhD, to serve as president for a two-year term. Dr. Bridges has served as the director of the University of Alabama–Birmingham (UAB) Division of Clinical Immunology and Rheumatology since 2009. He is also the director of the UAB Comprehensive Arthritis, Musculoskeletal, Bone and Autoimmunity…
Proposed Changes May Loosen Federal Fraud & Abuse Laws
The Stark law and the Anti-Kickback Statute (AKS) are the U.S. healthcare system’s primary fraud and abuse laws, and highly anticipated proposed reform plans from the Centers for Medicare & Medicaid Services (CMS) and the Office of Inspector General (OIG) were finally unveiled on Oct. 17, 2019. The proposed reforms would 1) clarify certain requirements…
5 Challenges in the Treatment & Diagnosis of Lupus
A recent study published in Lupus Science & Medicine lays out five of the top barriers impeding progress in lupus diagnosis and treatment.1 The Addressing Lupus Pillars for Health Advancement project (ALPHA), led by the Lupus Foundation of America (LFA), researchers at the Tufts School of Medicine Center for the Study of Drug Development (Tufts…
Study Finds an Indirect Association Between Sleep & Inflammation
In a study in Arthritis Care & Research, researchers showed an indirect association between osteoarthritis (OA) and sleep health in older men.1 In those participants with OA, the condition is associated with poorer sleep health, as well as a 16% higher incidence of elevated C-reactive protein and 12% higher odds of having elevated interleukin 6….
Copay Accumulator Programs Can Derail Rheumatologic Treatment Plans
As the medications for rheumatology become more expensive, the need for patient financial assistance becomes paramount. Unfortunately, commercially insured patients are finding it difficult to afford the exorbitant copays required by their plans, and the latest strategy of pharmacy benefit managers (PBMs) threatens to derail rheumatologic treatment goals. High deductible plans combined with copay accumulator…
- « Previous Page
- 1
- …
- 85
- 86
- 87
- 88
- 89
- …
- 304
- Next Page »